A Phase 1 interventional study of GBT021601 in Sickle Cell Disease, sponsored by Pfizer. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-25.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Anemia, Sickle Cell by Pfizer — 1 open to participants now, 1 under way, 1 of them phase 3. Anemia, Sickle Cell · Pfizer.
Among the 32 studies in Anemia, Sickle Cell by Pfizer, this one is the 10th largest by enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2020, is one of 10 in phase 1, and was the 22nd registered.
1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.
Browse Anemia, Sickle Cell studies →1 of the 32 studies in Anemia, Sickle Cell by Pfizer is open now, in 7 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Brazil, India and 4 more countries
Ages 12+
By country, each count listing its studies:
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 5 · Phase 3 11 · Phase 4 3
First in 2014; this study’s year is marked. 5 started in 2020.
This study's enrollment of 129 is above the median of 40 across 769 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 52 across the 27 interventional studies, 216 across the 3 observational. Of the 28 that completed or were terminated, 19 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 32 studies in Anemia, Sickle Cell by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This first in human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and food effect of GBT021601, a hemoglobin S (HbS) polymerization inhibitor, in healthy participants.
This is a randomized, double-blind, placebo controlled, single and multiple ascending dose study in healthy participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo as a tablet or capsule with dose based off of preceding cohort's data.
Drug: GBT021601
GBT021601 as a tablet or capsule with dose based off of preceding cohort's data.
Drug: GBT021601
Administered orally with water as a single dose in the morning.
Also known as: Placebo
Safety, as assessed by frequency and severity of adverse events (AEs)
AEs will be coded to system organ class and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA) and summarized.
Time frame: 119 days from screening Part A, 134 days from screening Part B
Safety, as assessed by changes in Heart Rate.
Number of participants with changes in heart rate (bpm) as compared to baseline.
Time frame: 119 days from screening Part A, 134 days from screening Part B
Safety, as assessed by changes in eGFR
Number of participants with changes in eGFR from baseline
Time frame: 119 days from screening Part A, 134 days from screening Part B
Safety, as assessed by changes in alanine aminotransferase (ALT)
Number of participants with changes in alanine aminotransferase (ALT)
Time frame: 119 days from screening Part A, 134 days from screening Part B
Safety, as assessed by changes in Blood pressure
Number of participants with changes in systolic (mmHg) and diastolic (mmHg) blood
Time frame: 119 days from screening Part A, 134 days from screening Part B
Plasma concentration
Time of Cmax
Time frame: 119 days from screening Part A
Plasma concentration
Cmax on D1-D15
Time frame: 134 days from screening Part B
Determine whole blood concentration of GBT021601
Hemoximetry will be used to assess oxygen saturation in whole blood by generating oxygen equilibrium curves (OECs) which relate the extent of Hb-O2 saturation to the partial pressure of O2 (pO2) and measure the binding affinity of O2 to Hb.
Time frame: 119 days from screening Part A
Determine plasma concentration of GBT021601.
With dosing data from each cohort determine the steady-state maximum plasma/whole blood concentration (Cmax).
Time frame: 134 days from screening Part B
Safety, as assessed by changes in QTcF
Number of participants with changes in the QTcF interval from baseline
Time frame: 119 days from screening Part A, 134 days from screening Part B
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
No publications or documents are linked to this record.
Ran from Dec 2020 to primary completion in Nov 2022, 22 months.
Of 28 industry-sponsored phase 1 interventional studies under Anemia, Sickle Cell, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's 22 months is close to that.
Counting every sponsor, half of 58 studies reached it within 36 months; a quarter within 18 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Osivelotor